Objective: To determine whether the acceleration/ejection time ratio of the fetal main pulmonary artery Doppler waveform (PATET) can accurately predict the results of fetal lung maturity testing in amniotic fluid. Methods: We prospectively studied pregnant women attending our ultrasound unit for clinically indicated fetal lung maturity testing. An ultrasound examination that included measurement of the PATET was performed before the results of the amniocentesis were reported. The results of the PATET and the surfactant/albumin ratio were compared, and a receiver operating characteristic curve was used to determine the PATET cutoff with the optimal sensitivity and specificity for predicting surfactant/albumin ratio results. p < 0.05 was considered statistically significant. Results: Forty-three patients were included in this study. The receiver operating characteristic curve demonstrated that a PATET cutoff of 0.3149 provided a specificity of 93% (95% CI 77-98%), a sensitivity of 73% (95% CI 48-89%), a negative predictive value of 87% (95% CI 70-95%), and a positive predictive value of 85% (95% CI 58-96%) for predicting immature surfactant/albumin ratio results. Conclusion: The PATET may provide a noninvasive means of determining fetal lung maturity with acceptable levels of sensitivity, specificity, and predictive values.

Keywords:
Fetal lung maturity, Prediction, Amniotic fluid
1.
American College of Obstetricians and Gynecologists: ACOG Practice Bulletin No. 97: fetal lung maturity. Obstet Gynecol 2008;112:717-726.
2.
Gordon MC, Narula K, O'Shaughnessy R, Barth WH Jr: Complications of third-trimester amniocentesis using continuous ultrasound guidance. Obstet Gynecol 2002;99:255-259.
3.
Sosa-Olavarria A, Diaz-Guerrero L: Indice relativo de impedancia Doppler de la arteria pulmonar y del ductus arterioso en embarazos pre-termino, a termino y post-termino. Rev Obstet Ginecol Venez 2000;60:97-101.
4.
Azpurua H, Norwitz ER, Campbell KH, et al: Acceleration/ejection time ratio in the fetal pulmonary artery predicts fetal lung maturity. Am J Obstet Gynecol 2010;203:40.e1-e8.
5.
American College of Obstetricians and Gynecologists: ACOG Practice Bulletin No. 101: ultrasonography in pregnancy. Obstet Gynecol 2009;113:451-461.
6.
Wladimiroff JW, Cohen-Overbeek TE, Laudy JA: Ultrasound evaluation of the fetal heart; in Callen PW: Ultrasonography in Obstetrics and Gynecology, ed 5. Philadelphia, Saunders/Elsevier, 2008, pp 514-515.
7.
Kitabatake A, Inoue M, Asao M, et al: Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation 1983;68:302-309.
8.
Kesselman EJ, Figueroa R, Garry D, Maulik D: The usefulness of the TDx/TDxFLx fetal lung maturity II assay in the initial evaluation of fetal lung maturity. Am J Obstet Gynecol 2003;188:1220-1222.
9.
Rasanen J, Huhta JC, Weiner S, Wood DC, Ludomirski A: Fetal branch pulmonary arterial vascular impedance during the second half of pregnancy. Am J Obstet Gynecol 1996;174:1441-1449.
10.
Grenache DG, Gronowski AM: Fetal lung maturity. Clin Biochem 2006;39:1-10.
11.
Moen A, Yu XQ, Almaas R, Curstedt T, Saugstad OD: Acute effects on systemic circulation after intratracheal instillation of Curosurf or Survanta in surfactant-depleted newborn piglets. Acta Paediatr 1998;87:297-303.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.